Climb Bio (CLYM) had its price target raised by Robert W. Baird from $9.00 to $12.00. They now have an "outperform" rating on the stock.
Climb Bio (CLYM) is now covered by Wedbush. They set an "outperform" rating and a $12.00 price target on the stock.
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Climb Bio (NASDAQ:CLYM) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.